Tag Archives: Difei Yang

Concert Pharma (CNCE) Received its Third Buy in a Row

After JMP Securities and H.C. Wainwright gave Concert Pharma (NASDAQ: CNCE) a Buy rating last month, the company received another Buy, this time from Mizuho Securities. Analyst Difei Yang maintained a Buy rating on Concert Pharma today and set a

Viveve Medical Inc (VIVE) Receives a Buy from Mizuho Securities

In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Viveve Medical Inc (VIVE – Research Report), with a price target of $4. The company’s shares closed on Friday at $2.32. Yang said: “We believe

Mizuho Securities Keeps a Buy Rating on Audentes Therapeutics (BOLD)

In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Audentes Therapeutics (BOLD – Research Report), with a price target of $45. The company’s shares closed yesterday at $29.56. Yang wrote: “We do not see

Mizuho Securities Sticks to Its Buy Rating for Aerie Pharma (AERI)

Mizuho Securities analyst Difei Yang reiterated a Buy rating on Aerie Pharma (AERI – Research Report) today and set a price target of $77. The company’s shares closed yesterday at $54.55. Yang commented: “We continue to believe that 2018 Rhopressa

Nektar Therapeutics (NKTR) Receives a Buy from Mizuho Securities

Mizuho Securities analyst Difei Yang maintained a Buy rating on Nektar Therapeutics (NKTR – Research Report) today and set a price target of $103. The company’s shares closed yesterday at $40. Yang observed: “We will be looking for an improvement

Mizuho Securities Reiterates Their Hold Rating on Achaogen (AKAO)

In a report released today, Difei Yang from Mizuho Securities reiterated a Hold rating on Achaogen (AKAO – Research Report). The company’s shares closed yesterday at $3.27, close to its 52-week low of $3.24. Yang observed: “We currently project a